Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on April 19, 2018, covering events reported as of April 13, 2018. The filing primarily addresses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure of CFO: John Golubieski resigned as Chief Financial Officer, effective May 9, 2018. The resignation was voluntary to pursue other opportunities and was not due to any disagreement with the Company.
- Appointment of New CFO: Nick Pizzie, CPA, MBA, was appointed as Chief Financial Officer, effective May 16, 2018.
- Interim Leadership: During the interim period between the resignation and the new appointment, CEO Herriot Tabuteau, M.D., serves as interim principal financial officer, and Joseph Debrah-Afful, CPA, MBA, serves as interim principal accounting officer.
Compensation and Arrangements
The filing details the compensatory arrangements for the new CFO, Mr. Pizzie:
- Base Salary: $325,000 annually (prorated based on the effective date).
- Target Bonus: 40% of annual base salary (not prorated).
- Sign-on Bonus: $15,000, subject to full repayment if he voluntarily leaves within one year.
- Equity Grant: 132,000 stock options under the 2015 Omnibus Incentive Plan. Vesting schedule: 25% on the first anniversary, with the remaining 75% vesting in equal quarterly increments over the subsequent three years.
- Severance: Eligible for 6 months of base salary if terminated without cause within 12 months following a change in control, contingent upon a separation agreement.
Outlook and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure regarding the transition of financial leadership. The Company confirmed the transition is intended to ensure continuity in financial operations.
Key Facts for Investor Verification
- Verify the exact effective dates for the resignation of John Golubieski (May 9, 2018) and the appointment of Nick Pizzie (May 16, 2018).
- Confirm the interim financial officer roles assigned to the CEO and Director of Finance during the transition gap.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the leadership change.
- Note that the Offer Letter terms are qualified by the full agreement, which is intended to be filed as an exhibit to the next periodic report.